Eradication therapy for helicobacter pylori in patients with gastric MALT lymphoma: A pooled data analysis

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 1932-1937

  Zullo, Angelo ^a   Hassan, Cesare ^a   Andriani, Alessandro ^b   Cristofari, Francesca ^a   De Francesco, Vincenzo ^c   Ierardi, Enzo ^c   Tomao, Silverio ^d   Morini, Sergio ^a   Vaira, Dino ^e  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b San Giacomo Hospital   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH SALT; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ARTICLE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; STOMACH LYMPHOMA;

DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; RECURRENCE; STATISTICS AS TOPIC; STOMACH NEOPLASMS;

EID: 68449095767     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.314     Document Type: Article

References (54)

1. Cavalli F, Isaacson PG, Gascoyne RD et al. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001, 241-58.
2. Wotherspoon AC. Choosing the right MALT. Gut 1996;39:617-8.
3. Stolte M, Bayerdörffer E, Morgner A et al. Helicobacter pylori and gastric MALT lymphoma. Gut 2002; 50 (Suppl 3): 19-24.
4. Andriani A, Zullo A, Di Raimondo F et al. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther 2006;23:721-6.
5. Nakamura S, Matsumoto T, Suekane H et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001;48:454-60.
6. Bayerdörffer E, Morgner A. Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease. Dig Liver Dis 2000;32:192-4.
7. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
8. Cavanna L, Pagani R, Seghini P et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol 2008;6:35.
9. Nakamura S, Matsumoto T, Iida M et al. Primary gastrointestinal lymphoma in Japan. A clinicopathologic analysis of 45. patients with special reference to its time trends. Cancer 2003;97:2462-73.
10. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
11. 2 values. Aliment Pharmacol Ther 2006;23:275-80.
12. Penston JG. Helicobacter pylori eradication: understandable caution but noexcuse for exertion. Aliment Pharmacol Ther 1994;8:369-79.
13. Zullo A, Rinaldi V, Hassan C et al. Clinical and histologic predictors of Helicobacter pylori infection recurrence. J Clin Gastroenterol 2000;31:38-41.
14. Fischbach W, Goebeler-Kolve ME, Dragosics B et al. Long-term outcome of patients with gastric marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-7.
15. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH et al. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut 2001;48:297-303.
16. Levy M, Copie-Bergman C, Traulle C et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002;97:292-7.
17. Wundisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-24.
18. Akamatsu T, Mochizuki T, Okiyama Y et al. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 2006;11:86-95.
19. Lee SK, Lee YC, Chung JB et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 1. year follow-up. World J Gastroenterol 2004;10:223-6.
20. Hong SS, Jung WY, Choi KD et al. A prospective analysis of low-grade gastric MALT lymphoma after Helicobacter pylori eradication. Helicobacter 2006;11:569-73.
21. Montalban C, Santon A, Redondo C et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann Oncol 2005;16:1539-44.
22. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999;131:88-95.
23. Ohashi S, Segawa K, Okamura S et al. Gastrin and Helicobacter pylori in lowgrade MALT lymphoma patients. Scand J Gastroenterol 2002;37:279-86.
24. Papa A, Cammarota G, Tursi A et al. Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Clin Gastroenterol 2000;31:169-71.
25. Caletti G, Zinzani PL, Fusaroli P et al. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. Aliment Pharmacol Ther 2002;16:1715-22.
26. Nakamura T, Seto M, Tajika M et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori and AP12-MALT1 status. Am J Gastroenterol 2008;103:62-70.
27. Nobre-Lietao C, Lage P, Cravo M et al. Treatment of gastric MALT lymphoma by Helicobacter pylorieradication: a study controlled by endoscopic ultrasonography. Am J Gastroenterol 1998;93:732-6.
28. Pinotti G, Zucca E, Roggero E et al. Clinical features, treatment and outcome in a series of 9. patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997;26:527-37.
29. Savio A, Franzin G, Wotherspoon AC et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996;87:1255-60.
30. Sugimoto M, Kajimura M, Shirai N et al. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern Med 2006;45:405-9.
31. Raderer M, Osterreicher C, Machold K et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 2001;12:937-9.
32. Ishii E, Yokota K, Sugiyama T et al. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 6. is closely associated with lowgrade gastric mucosa-associated lymphoid tissue lymphoma. Clin Diagn Lab Immunol 2001;8:1056-9.
33. Begum S, Sano T, Endo H et al. Mucosal change of the stomach with lowgrade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 4. cases. J Med Invest 2000;47:36-46.
34. Agresta F, Trentin G, Mainente P et al. Gastric malt lymphomas: the value of an endoscopic follow-up evaluation. Surg Endosc 2000;14:1153-5.
35. El-Zahabi LM, Jamali FR, El-Hajj II et al. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest Endosc 2007;65:89-96.
36. Kawahara Y, Mizuno M, Yoshino T et al. HLA-DQA1*0103-DQB1 *060. haplotype and Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2005;3:865-8.
37. Kim JS, Chung SJ, Choi YS et al. Helicobacter pyl orieradication for lowgrade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer 2007;96:1324-8.
38. Takenaka R, Yokota K, Mizuno M et al. Serum antibodies to Helicobacter pylori and its heat-shock protein 6. correlate with the response of gastric mucosa-associated lymphoid tissue lymphoma to eradication of H. pylori. Helicobacter 2004;9:194-200.
39. Yamashita H, Watanabe H, Ajioka Y et al. When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after Helicobacter pylori eradication? Histopathology 2000;37:131-40.
40. Ono S, Kato M, Ono Y et al. Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue, including changes after treatment. Gastrointest Endosc 2008;68:624-31.
41. Terai S, Iijima K, Kato K et al. Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med 2008;214:79-87.
42. Hiyama T, Haruma K, Kitadai Y et al. Microsatellite instability at D18S6. is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication. Oncol Rep 2001;8:293-7.
43. Morgner A, Miehlke S, Fischbach W et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001;19:2041-8.
44. Hiyama T, Haruma K, Kitadai Y et al. Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p5. and K-ras alteration and microsatellite instability. Int J Oncol 2001;18:1207-12.
45. Nakamura S, Matsumoto T, Suekane H et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005;104:532-40.
46. Venizelos I, Tamiolakis D, Lambropoulou M et al. Primary MALT lymphomas of the stomach: a pathological study of 1. cases. Rev Esp Enferm Dig 2007;99:270-4.
47. Chen LT, Lin JT, Tai JJ et al. Long-term results of anti- Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005;97:1345-53.
48. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut 2007;56:772-81.
49. Chey WD, Wong BCY. American College of Gastroenterology Guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1-18.
50. Fujioka T, Yoshiiwa A, Okimoto T et al. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J Gastroenterol 2007; 42 (Suppl 17): 3-6.
51. Caselli M, Zullo A, Maconi G et al. Cervia II Working Group Report 2006. guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-9.
52. Zullo A, Perna F, Hassan C et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in Northern and Central Italy. Aliment Pharmacol Ther 2007;25:1429-34.
53. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
54. Huang JQ, Zheng GF, Hunt RH et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005;11:2726-32.